ClinicalTrials.gg
CompletedNCT04943874Updated Oct 20, 2026Results posted

Biofeedback Based Virtual Reality Intervention to Manage Postoperative Pain

An interventional study of Technology Based Intervention Group 1 and Technology Based Intervention Group 2 in Pain, Pain, Postoperative and Pain, Acute, sponsored by Vanessa Olbrecht. Completed at 1 site in United States. Open to participants aged 12 Years to 18 Years. Per ClinicalTrials.gov, last updated 2026-10-20.

Sponsored by Vanessa Olbrecht · Not applicable, Interventional, and Other

How we know

Updated Oct 20, 2026Results postedPrimary outcomes revisedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
93
Allocation
Randomized
Ages
12 Years to 18 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 2,886 studies in Pain with a site in United States — 315 open to participants now, 393 under way, 24 of them phase 3. Pain · United States.

Enrollment
1,036th of 2,564
93 · median 66
Started
2022
with 93 others
No phase
1,244 of 2,886
183 open now
Registered
2,254th of 2,886
by date

Among the 2,886 studies in Pain with a site in United States, this one is the 1,036th largest by enrollment of the 2,564 interventional ones that give a count, is one of 94 that started in 2022, is one of 1,244 with no phase, and was the 2,254th registered.

Pain

10,076 studies on the registry are indexed under Pain; 1,648 are open to participants now.

Browse Pain studies →

Open to participants now

315 of the 2,886 studies in Pain with a site in United States are open now. Recruiting first, the newest first:

310 more — sign in →

All 315 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 930 Pain studies recruiting now, 384 (41%) set no upper age limit and 434 (47%) stop at 75 or younger; 146 take children under 18; 220 take healthy volunteers.

This study: 12 Years to 18 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 2,886 studies in Pain with a site in United States, or all of them as a file.
02

Study summary

To develop and refine a technology based treatment protocol for preoperative education and training and postoperative care in children and adolescents undergoing surgery.

Read the detailed description

This is a 2-phase study aimed to refine a perioperative treatment protocol for a technology-based intervention (Aim 1) and to understand whether technology-based interventions can be used to help treat pain in children following surgery (Aim 2). Patients will participate in only one phase of the study, and when patients are enrolled will determine what Phase of the study they are in.

In Phase 1, all patients will use the same technology, and no randomization will occur. Primary and secondary outcome measures of Aim 1 are assessed in Phase 1. Actual enrollment for Phase 1 was 23 patients.

In Phase 2, patients will be randomized to receive 1 of 2 technology-based interventions. The perioperative treatment protocol developed in Phase 1 (Aim 1) will be used in Phase 2 to assess the primary and secondary outcome measures of Aim 2. This phase is anticipated to enroll up to 70 participants.

This is not an FDA-regulated drug or device trial as the technology used in this study is categorized as a relaxation device by the FDA and considered "minimal risk", thus exempt from both NDE and IDE.

03

Conditions studied

  • Pain
  • Pain, Postoperative
  • Pain, Acute
  • Surgery
04

Who can participate

Ages eligible
12 Years to 18 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Ages 12 -18 years
  • Scheduled to undergo surgery anticipated to cause moderate to severe pain with expected length of stay > or = to 2 days
  • Able to read, understand and speak English
  • Patients requiring management by the Acute Pain Service
  • Possession of a mobile device/computer available for study participation

Exclusion criteria

Exclusion Criteria:

  • Outside the age range (\< 12 or > 18 years)
  • Non-English speaking
  • History of significant developmental delay, uncontrolled psychiatric conditions associated with hallucinations or delusions, or neurological conditions (especially epilepsy and/or significant motion sickness/nausea/vomiting)
  • History of vertigo, dizziness, seizure disorder, and/or severe motion sickness
  • History of chronic pain
  • Are chronically using opioids and or benzodiazepines for the management of pain
  • Are actively experiencing nausea or vomiting
  • Conditions such as craniofacial abnormalities or surgeries of the head and neck
  • Previous participation in this study
05

Study design

Phase
Not applicable
Primary purpose
Other
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Participant)
Enrollment
93 participants (actual)

Study arms

  • Other
    Technology Based Intervention 1 (Phase 1)

    Device: Technology Based Intervention Group 1

  • Other
    Technology Based Intervention 1 (Phase 2)

    Device: Technology Based Intervention Group 1

  • Other
    Technology Based Intervention 2 (Phase 2)

    Device: Technology Based Intervention Group 2

Interventions

  • DeviceTechnology Based Intervention Group 1

    In Phase 1, all participants will use the same technology. In Phase 2, participants will be blinded to the two specific groups. They will not be aware of the technology used in the group they are not assigned too.

  • DeviceTechnology Based Intervention Group 2

    Participants will be blinded to the two specific groups. They will not be aware of the technology used in the group they are not assigned too.

06

What researchers measure

Primary outcomes

  1. Aim 1 (Phase 1): Treatment Protocol Refinement

    The goal of Aim 1 (Phase 1) of this study was to refine a study (treatment) protocol for the application of the VR technology in children and adolescents undergoing surgery anticipated to cause moderate to severe pain. The study protocol developed in Phase 1 would then be used as the study protocol to assess feasibility and acceptability of the VR technology in Phase 2. The outcome measure for this primary aim was the number of participants from which data was used to help design the study protocol.

    Time frame: From two weeks before surgery up to 30 days after surgery

  2. Aim 2 (Phase 2): Feasibility of Technology Intervention in Perioperative Patients

    The primary goal of Aim 2 (Phase 2) of this study was to assess the feasibility of use of the VR technology in children and adolescents undergoing surgery anticipated to cause moderate to severe pain. We defined feasibility as the number of participants who were successfully enrolled and who completed study participation. Study participation was defined as completion of the final study visit.

    Time frame: From two weeks before surgery until 30 days after surgery

Secondary outcomes

  1. Aim 1 (Phase 1): Preoperative Training Protocol

    One of the secondary outcomes in Aim 1 (Phase 1) of this study was to determine how many preoperative VR technology sessions patients would complete to feel comfortable using the VR technology prior to surgery. This outcome measure was designed to help us understand how to design a clinical trial protocol for the subsequent feasibility and acceptability study that would be conducted in Phase 2. This outcome was measured as number of preoperative sessions completed by participants as a median, IQR.

    Time frame: Up to two weeks before surgery

  2. Aim 1 (Phase 1): Preoperative Training Protocol, Continued

    One of the secondary outcomes in Aim 1 (Phase 1) of this study was to determine how many preoperative VR technology sessions patients would complete to feel comfortable using the VR technology prior to surgery as well as their ability to maintain target heart rate parameters during this preoperative training. This outcome measure was designed to help us understand how to design a clinical trial protocol for the subsequent feasibility and acceptability study that would be conducted in Phase 2. This outcome measure specifically looked at the session number when target heartrate parameters were first met for \> 50% of the session duration as measured using HeartMath reported as a median, IQR.

    Time frame: Up to two weeks before surgery

  3. Aim 1 (Phase 1): Preoperative Training Protocol, Continued

    One of the secondary outcomes in Aim 1 (Phase 1) of this study was to determine how many preoperative VR technology sessions patients would complete to feel comfortable using the VR technology prior to surgery as well as their ability to maintain target heart rate parameters during this preoperative training. This outcome measure was designed to help us understand how to design a clinical trial protocol for the subsequent feasibility and acceptability study that would be conducted in Phase 2. This outcome measure specifically looked at the percentage of sessions in which patients maintained target heartrate parameters for \> 50% of the session duration (assessed using HeartMath), reported as a median, IQR.

    Time frame: Up to two weeks before surgery

  4. Aim 1 (Phase 1): Preoperative Training Protocol, Continued

    One of the secondary outcomes in Aim 1 (Phase 1) of the study was to determine how long participants would use the VR technology during each session prior to surgery. This outcome measure was designed to help us understand how to design a clinical trial protocol for the subsequent feasibility and acceptability study that would be conducted in Phase 2. The outcome was measured as the session duration in minutes (mean, standard deviation).

    Time frame: Up to two weeks before surgery

  5. Aim 1 (Phase 1): Post-operative Session Protocol

    One of the secondary outcomes in Aim 1 (Phase 1) of this study was to determine how many sessions patients would complete with the VR technology after surgery. Patients were given the option to use the technology for up to 14 days after surgery. This outcome measure was designed to help us understand how to design a clinical trial protocol for the subsequent feasibility and acceptability study that would be conducted in Phase 2. This outcome measured the number of postoperative sessions completed by participants as a median, IQR.

    Time frame: Up to two weeks after surgery

  6. Aim 1 (Phase 1): Post-operative Session Protocol, Continued

    One of the secondary outcomes in Aim 1 (Phase 1) of this study was to determine how many sessions patients would complete with the VR technology after surgery as well as their ability to maintain target heart rate parameters during these postoperative sessions. Patients were given the option to use the technology for up to 14 days after surgery. This outcome measure was designed to help us understand how to design a clinical trial protocol for the subsequent feasibility and acceptability study that would be conducted in Phase 2. This outcome measure specifically looked at the percentage of sessions in which patients maintained target heartrate parameters for \> 50% of the session duration (assessed using HeartMath), reported as a median, IQR.

    Time frame: Up to two weeks after surgery

  7. Aim 1 (Phase 1): Post-operative Session Protocol, Continued

    One of the secondary outcomes in Aim 1 (Phase 1) of this study was to determine how many sessions patients would complete with the VR technology after surgery as well as their ability to maintain target heart rate parameters during these postoperative sessions. Patients were given the option to use the technology for up to 14 days after surgery. This outcome measure was designed to help us understand how to design a clinical trial protocol for the subsequent feasibility and acceptability study that would be conducted in Phase 2. This outcome measure specifically looked at the session number when target heartrate parameters were first met for \> 50% of the session duration as measured using HeartMath reported as a median, IQR.

    Time frame: Up to two weeks after surgery

  8. Aim 1 (Phase 1): Postoperative Session Protocol, Continued

    One of the secondary outcomes in Aim 1 (Phase 1) of the study was to determine how long participants would use the VR technology during each session after surgery. Patients were given the option to use the technology for up to 14 days after surgery. This outcome measure was designed to help us understand how to design a clinical trial protocol for the subsequent feasibility and acceptability study that would be conducted in Phase 2. The outcome was measured as the session duration in minutes (mean, standard deviation).

    Time frame: Up to two weeks after surgery

  9. Aim 2 (Phase 2): Rate of Study Enrollment/Randomization

    As a measure of feasibility in Phase 2 (Aim 2) of the study, we evaluated our ability to enroll participants in the study as defined as the number of patients who were successfully enrolled and agreed to be randomized to a treatment arm. A total of 70 patients were enrolled, and all 70 participants agreed to be randomized.

    Time frame: Pre-intervention up to 2 weeks before surgery

  10. Aim 2 (Phase 2): Rate of Study Retention

    As a measure of feasibility in Phase 2 (Aim 2) of the study, we evaluated the ability to retain patients in the study. Retention was defined as the number of patients who completed the final study visit.

    Time frame: From two weeks before surgery up to 30 days after surgery

  11. Aim 2 (Phase 2): Rate of Treatment Adherence (Preoperative)

    As a measure of acceptability in Phase 2 (Aim 2) of the study, we evaluated the number of participants who participated in study activities both pre- and postoperatively. Treatment adherence was defined as the number of participants who completed at least one study activity in each respective time period (before and after surgery). This outcome measure assessed the number of participants who adhered to treatment preoperatively as measured by participant count.

    Time frame: Up to 2 weeks before surgery

  12. Aim 2 (Phase 2): Treatment Adherence, Continued (Preoperative)

    As a measure of acceptability in Phase 2 (Aim 2) of the study, we evaluated participation in study activities both pre- and postoperatively. We evaluated the median number of days in which participants completed at least one technology session and the median number of days in which participants completed at least one diary entry preoperatively (before surgery). We also evaluated the total number of technology sessions done per participant after surgery, the median number of days in which the technology was used after surgery, and the median number of technology sessions per day per participant. Participants who completed at least one session during the study period were included in analysis. This outcome measure evaluates the number of days in which patients completed a technology session preoperatively, reported as median, IQR.

    Time frame: Up to two weeks before surgery

  13. Aim 2 (Phase 2): Treatment Adherence, Continued (Preoperative)

    As a measure of acceptability in Phase 2 (Aim 2) of the study, we evaluated participation in study activities both pre- and postoperatively. We evaluated the median number of days in which participants completed at least one technology session and the median number of days in which participants completed at least one diary entry preoperatively (before surgery). We also evaluated the total number of technology sessions done per participant after surgery, the median number of days in which the technology was used after surgery, and the median number of technology sessions per day per participant. Participants who completed at least one session during the study period were included in analysis. This outcome measure evaluates the number of days in which participants completed a diary entry before surgery, as reported as a median, IQR.

    Time frame: Up to two weeks before surgery

  14. Aim 2 (Phase 2): Rate of Treatment Adherence (Post-operative)

    As a measure of acceptability in Phase 2 (Aim 2) of the study, we evaluated the number of participants who participated in study activities both pre- and postoperatively. Treatment adherence was defined as the number of participants who completed at least one study activity in each respective time period (before and after surgery). This outcome measure assessed the number of participants who adhered to treatment post-operatively as measured by participant count.

    Time frame: Up to 30 days after surgery

  15. Aim 2 (Phase 2): Treatment Adherence, Continued (Post-operative)

    As a measure of acceptability in Phase 2 (Aim 2) of the study, we evaluated participation in study activities both pre- and postoperatively. We evaluated the median number of days in which participants completed at least one technology session and the median number of days in which participants completed at least one diary entry preoperatively (before surgery). We also evaluated the total number of technology sessions done per participant after surgery, the median number of days in which the technology was used after surgery, and the median number of technology sessions per day per participant. Participants who completed at least one session during the study period were included in analysis. This outcome measure evaluates the total number of completed technology sessions after surgery by participants, reported as a median, IQR.

    Time frame: Up to 30 days after surgery

  16. Aim 2 (Phase 2): Treatment Adherence, Continued (Post-operative)

    As a measure of acceptability in Phase 2 (Aim 2) of the study, we evaluated participation in study activities both pre- and postoperatively. We evaluated the median number of days in which participants completed at least one technology session and the median number of days in which participants completed at least one diary entry preoperatively (before surgery). We also evaluated the total number of technology sessions done per participant after surgery, the median number of days in which the technology was used after surgery, and the median number of technology sessions per day per participant. Participants who completed at least one session during the study period were included in analysis. This outcome measure evaluates the total number of completed diary entries after surgery by participants, reported as a median, IQR.

    Time frame: Up to 30 days after surgery

  17. Aim 2 (Phase 2): Treatment Adherence, Continued (Post-operative)

    As a measure of acceptability in Phase 2 (Aim 2) of the study, we evaluated participation in study activities both pre- and postoperatively. We evaluated the median number of days in which participants completed at least one technology session and the median number of days in which participants completed at least one diary entry preoperatively (before surgery). We also evaluated the total number of technology sessions done per participant after surgery, the median number of days in which the technology was used after surgery, and the median number of technology sessions per day per participant. Participants who completed at least one session during the study period were included in analysis. This outcome measure evaluates the median number of days in which the assigned technology was used by participants after surgery, reported as a median, IQR.

    Time frame: Up to 30 days

  18. Aim 2 (Phase 2): Treatment Adherence, Continued (Post-operative)

    As a measure of acceptability in Phase 2 (Aim 2) of the study, we evaluated participation in study activities both pre- and postoperatively. We evaluated the median number of days in which participants completed at least one technology session and the median number of days in which participants completed at least one diary entry preoperatively (before surgery). We also evaluated the total number of technology sessions done per participant after surgery, the median number of days in which the technology was used after surgery, and the median number of technology sessions per day per participant. Participants who completed at least one session during the study period were included in analysis. This outcome measure evaluates the median number of technology sessions completed per day by participants after surgery, reported as median, IQR.

    Time frame: Up to 30 days after surgery

  19. Aim 2 (Phase 2): Treatment-specific Satisfaction

    As a measure of acceptability in Phase 2 (Aim 2) of the study, we evaluated the number of patients who completed the end-of-study surveys/questionnaires.

    Time frame: Duration of study participation up to 30 days

  20. Aim 2 (Phase 2): Feasibility of Anxiety Outcome Data Collection

    One of the secondary outcomes in Aim 2 (Phase 2) was to evaluate the feasibility of collecting data of clinical outcomes that would serve as the basis for efficacy evaluation of the interventions in future clinical trials. We evaluated the ability to collect 3 subjective clinical outcomes: pain intensity, pain unpleasantness, and anxiety scores immediately before a technology session preoperatively and immediately before, immediately after, 15-minutes after, and 30-minutes after a technology session after surgery in both treatment arms. Preoperatively, scores were collected only at one time point during the 5 preoperative days. In this measure, we evaluated the number of participants reporting at least one anxiety score for each time point during study participation. Because this study was a study designed to assess feasibility, we did not evaluate/analyze the scores themselves but rather our ability to collect the data from participants.

    Time frame: Up to 2 weeks before surgery and up to 2 weeks after surgery

  21. Aim 2 (Phase 2): Feasibility of Anxiety Outcome Data Collection, Continued

    One of the secondary outcomes in Aim 2 (Phase 2) of the study was to evaluate the feasibility of collecting data of clinical outcomes that would serve as the basis for efficacy evaluation of the interventions in future clinical trials. We evaluated the ability to collect 3 subjective clinical outcomes: pain intensity, pain unpleasantness, and anxiety scores immediately before a technology session preoperatively and immediately before, immediately after, 15-minutes after, and 30-minutes after a technology session after surgery in both treatment arms. In this measure, we evaluated the median number of anxiety scores reported by participants for each time point after surgery during their study participation as a median, IQR. Because this study was a study designed to assess feasibility, we did not evaluate/analyze the scores themselves but rather our ability to collect the data.

    Time frame: Up to 2 weeks after surgery

  22. Aim 2 (Phase 2): Feasibility of Pain Unpleasantness Outcome Data Collection

    One of the secondary outcomes in Aim 2 (Phase 2) was to evaluate the feasibility of collecting data of clinical outcomes that would serve as the basis for efficacy evaluation of the interventions in future clinical trials. We evaluated the ability to collect 3 subjective clinical outcomes: pain intensity, pain unpleasantness, and anxiety scores immediately before a technology session preoperatively and immediately before, immediately after, 15-minutes after, and 30-minutes after a technology session after surgery in both treatment arms. Preoperatively, scores were collected only at one time point during the 5 preoperative days. In this measure, we evaluated the number of participants reporting at least one pain unpleasantness score for each time point during study participation. Because this study was a study designed to assess feasibility, we did not evaluate/analyze the scores themselves but rather our ability to collect data from participants

    Time frame: Up to 2 weeks before surgery and up to 2 weeks after surgery

  23. Aim 2 (Phase 2): Feasibility of Pain Unpleasantness Outcome Data Collection, Continued

    One of the secondary outcomes in Aim 2 (Phase 2) of the study was to evaluate the feasibility of collecting data of clinical outcomes that would serve as the basis for efficacy evaluation of the interventions in future clinical trials. We evaluated the ability to collect 3 subjective clinical outcomes: pain intensity, pain unpleasantness, and anxiety scores immediately before a technology session preoperatively and immediately before, immediately after, 15-minutes after, and 30-minutes after a technology session after surgery in both treatment arms. In this measure, we evaluated the median number of pain unpleasantness scores reported by participants for each time point after surgery during their study participation as a median, IQR. Because this study was a study designed to assess feasibility, we did not evaluate/analyze the scores themselves but rather our ability to collect the data.

    Time frame: Up to 2 weeks after surgery

  24. Aim 2 (Phase 2): Feasibility of Pain Intensity Outcome Data Collection

    One of the secondary outcomes in Aim 2 (Phase 2) was to evaluate the feasibility of collecting data of clinical outcomes that would serve as the basis for efficacy evaluation of the interventions in future clinical trials. We evaluated the ability to collect 3 subjective clinical outcomes: pain intensity, pain unpleasantness, and anxiety scores immediately before a technology session preoperatively and immediately before, immediately after, 15-minutes after, and 30-minutes after a technology session after surgery in both treatment arms. Preoperatively, scores were collected only at one time point during the 5 preoperative days. In this measure, we evaluated the number of participants reporting at least one pain intensity score for each time point during study participation. Because this study was a study designed to assess feasibility, we did not evaluate/analyze the scores themselves but rather our ability to collect data from participants.

    Time frame: Up to 2 weeks before surgery and up to 2 weeks after surgery

  25. Aim 2 (Phase 2): Feasibility of Pain Intensity Outcome Data Collection, Continued

    One of the secondary outcomes in Aim 2 (Phase 2) of the study was to evaluate the feasibility of collecting data of clinical outcomes that would serve as the basis for efficacy evaluation of the interventions in future clinical trials. We evaluated the ability to collect 3 subjective clinical outcomes: pain intensity, pain unpleasantness, and anxiety scores immediately before a technology session preoperatively and immediately before, immediately after, 15-minutes after, and 30-minutes after a technology session after surgery in both treatment arms. In this measure, we evaluated the median number of pain intensity scores reported by participants for each time point after surgery during their study participation as a median, IQR. Because this study was a study designed to assess feasibility, we did not evaluate/analyze the scores themselves but rather our ability to collect the data.

    Time frame: Up to 2 weeks after surgery

  26. Aim 2 (Phase 2): Feasibility of Medication Use Data Collection

    One of the secondary outcomes in Aim 2 (Phase 2) of the study was to evaluate the feasibility of collecting data of clinical outcomes that would serve as the basis for efficacy evaluation of the interventions in future clinical trials. We evaluated the ability to collect opioid use postoperatively. In this measure, we evaluated the number of patients in which opioid use data was successfully collected after surgery.

    Time frame: Post-intervention up to 7 days

07

Results

Posted Oct 20, 2026

Participant flow

Participant flow — Overall Study
MilestoneTechnology Based Intervention 1 (Aim 1/Phase 1)Technology Based Intervention 1 (Aim 2/Phase 2)Technology Based Intervention 2 (Aim 2/Phase 2)
Started233931
Completed233530
Not completed041

Outcome measures

PrimaryAim 1 (Phase 1): Treatment Protocol Refinement

The goal of Aim 1 (Phase 1) of this study was to refine a study (treatment) protocol for the application of the VR technology in children and adolescents undergoing surgery anticipated to cause moderate to severe pain. The study protocol developed in Phase 1 would then be used as the study protocol to assess feasibility and acceptability of the VR technology in Phase 2. The outcome measure for this primary aim was the number of participants from which data was used to help design the study protocol.

Time frame:
From two weeks before surgery up to 30 days after surgery
Reported as:
Count of participants · Participants
Aim 1 (Phase 1): Treatment Protocol Refinement
ParticipantsTechnology Based Intervention 1 (Aim 1/Phase 1)
Aim 1 (Phase 1): Treatment Protocol Refinement23 (4 to 7)
PrimaryAim 2 (Phase 2): Feasibility of Technology Intervention in Perioperative Patients

The primary goal of Aim 2 (Phase 2) of this study was to assess the feasibility of use of the VR technology in children and adolescents undergoing surgery anticipated to cause moderate to severe pain. We defined feasibility as the number of participants who were successfully enrolled and who completed study participation. Study participation was defined as completion of the final study visit.

Time frame:
From two weeks before surgery until 30 days after surgery
Reported as:
Count of participants · Participants
Aim 2 (Phase 2): Feasibility of Technology Intervention in Perioperative Patients
ParticipantsTechnology Based Intervention 1 (Aim 2/Phase 2)Technology Based Intervention 2 (Aim 2/Phase 2)
Aim 2 (Phase 2): Feasibility of Technology Intervention in Perioperative Patients3530
SecondaryAim 1 (Phase 1): Preoperative Training Protocol

One of the secondary outcomes in Aim 1 (Phase 1) of this study was to determine how many preoperative VR technology sessions patients would complete to feel comfortable using the VR technology prior to surgery. This outcome measure was designed to help us understand how to design a clinical trial protocol for the subsequent feasibility and acceptability study that would be conducted in Phase 2. This outcome was measured as number of preoperative sessions completed by participants as a median, IQR.

Time frame:
Up to two weeks before surgery
Reported as:
Median · Number of sessions
Aim 1 (Phase 1): Preoperative Training Protocol
Number of sessionsTechnology Based Intervention 1 (Phase 1)
Aim 1 (Phase 1): Preoperative Training Protocol6 (4 to 7)
SecondaryAim 1 (Phase 1): Preoperative Training Protocol, Continued

One of the secondary outcomes in Aim 1 (Phase 1) of this study was to determine how many preoperative VR technology sessions patients would complete to feel comfortable using the VR technology prior to surgery as well as their ability to maintain target heart rate parameters during this preoperative training. This outcome measure was designed to help us understand how to design a clinical trial protocol for the subsequent feasibility and acceptability study that would be conducted in Phase 2. This outcome measure specifically looked at the session number when target heartrate parameters were first met for \> 50% of the session duration as measured using HeartMath reported as a median, IQR.

Time frame:
Up to two weeks before surgery
Reported as:
Median · Session number
Aim 1 (Phase 1): Preoperative Training Protocol, Continued
Session numberTechnology Based Intervention 1 (Phase 1)
Aim 1 (Phase 1): Preoperative Training Protocol, Continued1 (1 to 1)
SecondaryAim 1 (Phase 1): Preoperative Training Protocol, Continued

One of the secondary outcomes in Aim 1 (Phase 1) of this study was to determine how many preoperative VR technology sessions patients would complete to feel comfortable using the VR technology prior to surgery as well as their ability to maintain target heart rate parameters during this preoperative training. This outcome measure was designed to help us understand how to design a clinical trial protocol for the subsequent feasibility and acceptability study that would be conducted in Phase 2. This outcome measure specifically looked at the percentage of sessions in which patients maintained target heartrate parameters for \> 50% of the session duration (assessed using HeartMath), reported as a median, IQR.

Time frame:
Up to two weeks before surgery
Reported as:
Median · Percentage of Sessions
Aim 1 (Phase 1): Preoperative Training Protocol, Continued
Percentage of SessionsTechnology Based Intervention 1 (Phase 1)
Aim 1 (Phase 1): Preoperative Training Protocol, Continued100 (86 to 100)
SecondaryAim 1 (Phase 1): Preoperative Training Protocol, Continued

One of the secondary outcomes in Aim 1 (Phase 1) of the study was to determine how long participants would use the VR technology during each session prior to surgery. This outcome measure was designed to help us understand how to design a clinical trial protocol for the subsequent feasibility and acceptability study that would be conducted in Phase 2. The outcome was measured as the session duration in minutes (mean, standard deviation).

Time frame:
Up to two weeks before surgery
Reported as:
Mean · Minutes
Aim 1 (Phase 1): Preoperative Training Protocol, Continued
MinutesTechnology Based Intervention 1 (Phase 1)
Aim 1 (Phase 1): Preoperative Training Protocol, Continued9.6 ± 2.3
SecondaryAim 1 (Phase 1): Post-operative Session Protocol

One of the secondary outcomes in Aim 1 (Phase 1) of this study was to determine how many sessions patients would complete with the VR technology after surgery. Patients were given the option to use the technology for up to 14 days after surgery. This outcome measure was designed to help us understand how to design a clinical trial protocol for the subsequent feasibility and acceptability study that would be conducted in Phase 2. This outcome measured the number of postoperative sessions completed by participants as a median, IQR.

Time frame:
Up to two weeks after surgery
Reported as:
Median · Number of sessions
Aim 1 (Phase 1): Post-operative Session Protocol
Number of sessionsTechnology Based Intervention 1 (Phase 1)
Aim 1 (Phase 1): Post-operative Session Protocol2 (1 to 2.5)
SecondaryAim 1 (Phase 1): Post-operative Session Protocol, Continued

One of the secondary outcomes in Aim 1 (Phase 1) of this study was to determine how many sessions patients would complete with the VR technology after surgery as well as their ability to maintain target heart rate parameters during these postoperative sessions. Patients were given the option to use the technology for up to 14 days after surgery. This outcome measure was designed to help us understand how to design a clinical trial protocol for the subsequent feasibility and acceptability study that would be conducted in Phase 2. This outcome measure specifically looked at the percentage of sessions in which patients maintained target heartrate parameters for \> 50% of the session duration (assessed using HeartMath), reported as a median, IQR.

Time frame:
Up to two weeks after surgery
Reported as:
Median · Percentage of sessions
Aim 1 (Phase 1): Post-operative Session Protocol, Continued
Percentage of sessionsTechnology Based Intervention 1 (Phase 1)
Aim 1 (Phase 1): Post-operative Session Protocol, Continued83 (42 to 100)
SecondaryAim 1 (Phase 1): Post-operative Session Protocol, Continued

One of the secondary outcomes in Aim 1 (Phase 1) of this study was to determine how many sessions patients would complete with the VR technology after surgery as well as their ability to maintain target heart rate parameters during these postoperative sessions. Patients were given the option to use the technology for up to 14 days after surgery. This outcome measure was designed to help us understand how to design a clinical trial protocol for the subsequent feasibility and acceptability study that would be conducted in Phase 2. This outcome measure specifically looked at the session number when target heartrate parameters were first met for \> 50% of the session duration as measured using HeartMath reported as a median, IQR.

Time frame:
Up to two weeks after surgery
Reported as:
Median · Session number
Aim 1 (Phase 1): Post-operative Session Protocol, Continued
Session numberTechnology Based Intervention 1 (Phase 1)
Aim 1 (Phase 1): Post-operative Session Protocol, Continued1 (1 to 1)
SecondaryAim 1 (Phase 1): Postoperative Session Protocol, Continued

One of the secondary outcomes in Aim 1 (Phase 1) of the study was to determine how long participants would use the VR technology during each session after surgery. Patients were given the option to use the technology for up to 14 days after surgery. This outcome measure was designed to help us understand how to design a clinical trial protocol for the subsequent feasibility and acceptability study that would be conducted in Phase 2. The outcome was measured as the session duration in minutes (mean, standard deviation).

Time frame:
Up to two weeks after surgery
Reported as:
Mean · Minutes
Aim 1 (Phase 1): Postoperative Session Protocol, Continued
MinutesTechnology Based Intervention 1 (Phase 1)
Aim 1 (Phase 1): Postoperative Session Protocol, Continued9.5 ± 2.3
SecondaryAim 2 (Phase 2): Rate of Study Enrollment/Randomization

As a measure of feasibility in Phase 2 (Aim 2) of the study, we evaluated our ability to enroll participants in the study as defined as the number of patients who were successfully enrolled and agreed to be randomized to a treatment arm. A total of 70 patients were enrolled, and all 70 participants agreed to be randomized.

Time frame:
Pre-intervention up to 2 weeks before surgery
Reported as:
Count of participants · Participants
Aim 2 (Phase 2): Rate of Study Enrollment/Randomization
ParticipantsTechnology Based Intervention 1 (Phase 2)Technology Based Intervention 2 (Phase 2)
Aim 2 (Phase 2): Rate of Study Enrollment/Randomization3931
SecondaryAim 2 (Phase 2): Rate of Study Retention

As a measure of feasibility in Phase 2 (Aim 2) of the study, we evaluated the ability to retain patients in the study. Retention was defined as the number of patients who completed the final study visit.

Time frame:
From two weeks before surgery up to 30 days after surgery
Reported as:
Count of participants · Participants
Aim 2 (Phase 2): Rate of Study Retention
ParticipantsTechnology Based Intervention 1 (Phase 2)Technology Based Intervention 2 (Phase 2)
Aim 2 (Phase 2): Rate of Study Retention3530
SecondaryAim 2 (Phase 2): Rate of Treatment Adherence (Preoperative)

As a measure of acceptability in Phase 2 (Aim 2) of the study, we evaluated the number of participants who participated in study activities both pre- and postoperatively. Treatment adherence was defined as the number of participants who completed at least one study activity in each respective time period (before and after surgery). This outcome measure assessed the number of participants who adhered to treatment preoperatively as measured by participant count.

Time frame:
Up to 2 weeks before surgery
Reported as:
Count of participants · Participants
Aim 2 (Phase 2): Rate of Treatment Adherence (Preoperative)
ParticipantsTechnology Based Intervention 1 (Phase 2)Technology Based Intervention 2 (Phase 2)
Aim 2 (Phase 2): Rate of Treatment Adherence (Preoperative)3529
SecondaryAim 2 (Phase 2): Treatment Adherence, Continued (Preoperative)

As a measure of acceptability in Phase 2 (Aim 2) of the study, we evaluated participation in study activities both pre- and postoperatively. We evaluated the median number of days in which participants completed at least one technology session and the median number of days in which participants completed at least one diary entry preoperatively (before surgery). We also evaluated the total number of technology sessions done per participant after surgery, the median number of days in which the technology was used after surgery, and the median number of technology sessions per day per participant. Participants who completed at least one session during the study period were included in analysis. This outcome measure evaluates the number of days in which patients completed a technology session preoperatively, reported as median, IQR.

Time frame:
Up to two weeks before surgery
Reported as:
Median · Days
Aim 2 (Phase 2): Treatment Adherence, Continued (Preoperative)
DaysTechnology Based Intervention 1 (Phase 2)Technology Based Intervention 2 (Phase 2)
Aim 2 (Phase 2): Treatment Adherence, Continued (Preoperative)5 (4 to 5)4 (3 to 5)
SecondaryAim 2 (Phase 2): Treatment Adherence, Continued (Preoperative)

As a measure of acceptability in Phase 2 (Aim 2) of the study, we evaluated participation in study activities both pre- and postoperatively. We evaluated the median number of days in which participants completed at least one technology session and the median number of days in which participants completed at least one diary entry preoperatively (before surgery). We also evaluated the total number of technology sessions done per participant after surgery, the median number of days in which the technology was used after surgery, and the median number of technology sessions per day per participant. Participants who completed at least one session during the study period were included in analysis. This outcome measure evaluates the number of days in which participants completed a diary entry before surgery, as reported as a median, IQR.

Time frame:
Up to two weeks before surgery
Reported as:
Median · Days
Aim 2 (Phase 2): Treatment Adherence, Continued (Preoperative)
DaysTechnology Based Intervention 1 (Phase 2)Technology Based Intervention 2 (Phase 2)
Aim 2 (Phase 2): Treatment Adherence, Continued (Preoperative)5 (4 to 5)5 (3 to 5)
SecondaryAim 2 (Phase 2): Rate of Treatment Adherence (Post-operative)

As a measure of acceptability in Phase 2 (Aim 2) of the study, we evaluated the number of participants who participated in study activities both pre- and postoperatively. Treatment adherence was defined as the number of participants who completed at least one study activity in each respective time period (before and after surgery). This outcome measure assessed the number of participants who adhered to treatment post-operatively as measured by participant count.

Time frame:
Up to 30 days after surgery
Reported as:
Count of participants · Participants
Aim 2 (Phase 2): Rate of Treatment Adherence (Post-operative)
ParticipantsTechnology Based Intervention 1 (Phase 2)Technology Based Intervention 2 (Phase 2)
Aim 2 (Phase 2): Rate of Treatment Adherence (Post-operative)3426
SecondaryAim 2 (Phase 2): Treatment Adherence, Continued (Post-operative)

As a measure of acceptability in Phase 2 (Aim 2) of the study, we evaluated participation in study activities both pre- and postoperatively. We evaluated the median number of days in which participants completed at least one technology session and the median number of days in which participants completed at least one diary entry preoperatively (before surgery). We also evaluated the total number of technology sessions done per participant after surgery, the median number of days in which the technology was used after surgery, and the median number of technology sessions per day per participant. Participants who completed at least one session during the study period were included in analysis. This outcome measure evaluates the total number of completed technology sessions after surgery by participants, reported as a median, IQR.

Time frame:
Up to 30 days after surgery
Reported as:
Median · Technology sessions
Aim 2 (Phase 2): Treatment Adherence, Continued (Post-operative)
Technology sessionsTechnology Based Intervention 1 (Phase 2)Technology Based Intervention 2 (Phase 2)
Aim 2 (Phase 2): Treatment Adherence, Continued (Post-operative)8 (5 to 13)7 (2 to 9)
SecondaryAim 2 (Phase 2): Treatment Adherence, Continued (Post-operative)

As a measure of acceptability in Phase 2 (Aim 2) of the study, we evaluated participation in study activities both pre- and postoperatively. We evaluated the median number of days in which participants completed at least one technology session and the median number of days in which participants completed at least one diary entry preoperatively (before surgery). We also evaluated the total number of technology sessions done per participant after surgery, the median number of days in which the technology was used after surgery, and the median number of technology sessions per day per participant. Participants who completed at least one session during the study period were included in analysis. This outcome measure evaluates the total number of completed diary entries after surgery by participants, reported as a median, IQR.

Time frame:
Up to 30 days after surgery
Reported as:
Median · Diary entries
Aim 2 (Phase 2): Treatment Adherence, Continued (Post-operative)
Diary entriesTechnology Based Intervention 1 (Phase 2)Technology Based Intervention 2 (Phase 2)
Aim 2 (Phase 2): Treatment Adherence, Continued (Post-operative)11.5 (6 to 15)12.5 (5 to 16)
SecondaryAim 2 (Phase 2): Treatment Adherence, Continued (Post-operative)

As a measure of acceptability in Phase 2 (Aim 2) of the study, we evaluated participation in study activities both pre- and postoperatively. We evaluated the median number of days in which participants completed at least one technology session and the median number of days in which participants completed at least one diary entry preoperatively (before surgery). We also evaluated the total number of technology sessions done per participant after surgery, the median number of days in which the technology was used after surgery, and the median number of technology sessions per day per participant. Participants who completed at least one session during the study period were included in analysis. This outcome measure evaluates the median number of days in which the assigned technology was used by participants after surgery, reported as a median, IQR.

Time frame:
Up to 30 days
Reported as:
Median · Days
Aim 2 (Phase 2): Treatment Adherence, Continued (Post-operative)
DaysTechnology Based Intervention 1 (Phase 2)Technology Based Intervention 2 (Phase 2)
Aim 2 (Phase 2): Treatment Adherence, Continued (Post-operative)5 (4 to 5)4 (2 to 5)
SecondaryAim 2 (Phase 2): Treatment Adherence, Continued (Post-operative)

As a measure of acceptability in Phase 2 (Aim 2) of the study, we evaluated participation in study activities both pre- and postoperatively. We evaluated the median number of days in which participants completed at least one technology session and the median number of days in which participants completed at least one diary entry preoperatively (before surgery). We also evaluated the total number of technology sessions done per participant after surgery, the median number of days in which the technology was used after surgery, and the median number of technology sessions per day per participant. Participants who completed at least one session during the study period were included in analysis. This outcome measure evaluates the median number of technology sessions completed per day by participants after surgery, reported as median, IQR.

Time frame:
Up to 30 days after surgery
Reported as:
Median · Technology sessions per day
Aim 2 (Phase 2): Treatment Adherence, Continued (Post-operative)
Technology sessions per dayTechnology Based Intervention 1 (Phase 2)Technology Based Intervention 2 (Phase 2)
Aim 2 (Phase 2): Treatment Adherence, Continued (Post-operative)2 (1.6 to 2.6)2 (1.6 to 2.4)
SecondaryAim 2 (Phase 2): Treatment-specific Satisfaction

As a measure of acceptability in Phase 2 (Aim 2) of the study, we evaluated the number of patients who completed the end-of-study surveys/questionnaires.

Time frame:
Duration of study participation up to 30 days
Reported as:
Count of participants · Participants
Aim 2 (Phase 2): Treatment-specific Satisfaction
ParticipantsTechnology Based Intervention 1 (Phase 2)Technology Based Intervention 2 (Phase 2)
Aim 2 (Phase 2): Treatment-specific Satisfaction3530
SecondaryAim 2 (Phase 2): Feasibility of Anxiety Outcome Data Collection

One of the secondary outcomes in Aim 2 (Phase 2) was to evaluate the feasibility of collecting data of clinical outcomes that would serve as the basis for efficacy evaluation of the interventions in future clinical trials. We evaluated the ability to collect 3 subjective clinical outcomes: pain intensity, pain unpleasantness, and anxiety scores immediately before a technology session preoperatively and immediately before, immediately after, 15-minutes after, and 30-minutes after a technology session after surgery in both treatment arms. Preoperatively, scores were collected only at one time point during the 5 preoperative days. In this measure, we evaluated the number of participants reporting at least one anxiety score for each time point during study participation. Because this study was a study designed to assess feasibility, we did not evaluate/analyze the scores themselves but rather our ability to collect the data from participants.

Time frame:
Up to 2 weeks before surgery and up to 2 weeks after surgery
Reported as:
Count of participants · Participants
Aim 2 (Phase 2): Feasibility of Anxiety Outcome Data Collection
ParticipantsTechnology Based Intervention 1 (Phase 2)Technology Based Intervention 2 (Phase 2)
Preoperative, immediately before session2621
Postoperative, immediately before session3527
Postoperative, immediately after session3524
Postoperative, 15 minutes after session3524
Postoperative, 30 minutes after session3524
SecondaryAim 2 (Phase 2): Feasibility of Anxiety Outcome Data Collection, Continued

One of the secondary outcomes in Aim 2 (Phase 2) of the study was to evaluate the feasibility of collecting data of clinical outcomes that would serve as the basis for efficacy evaluation of the interventions in future clinical trials. We evaluated the ability to collect 3 subjective clinical outcomes: pain intensity, pain unpleasantness, and anxiety scores immediately before a technology session preoperatively and immediately before, immediately after, 15-minutes after, and 30-minutes after a technology session after surgery in both treatment arms. In this measure, we evaluated the median number of anxiety scores reported by participants for each time point after surgery during their study participation as a median, IQR. Because this study was a study designed to assess feasibility, we did not evaluate/analyze the scores themselves but rather our ability to collect the data.

Time frame:
Up to 2 weeks after surgery
Reported as:
Median · Number of anxiety scores reported
Aim 2 (Phase 2): Feasibility of Anxiety Outcome Data Collection, Continued
Number of anxiety scores reportedTechnology Based Intervention 1 (Phase 2)Technology Based Intervention 2 (Phase 2)
Postoperative, immediately before session12 (6 to 16)12 (4 to 16)
Postoperative, immediately after session10 (6 to 15)8 (2 to 10)
Postoperative, 15 minutes after session10 (6 to 15)8 (2 to 12)
Postoperative, 30 minutes after session10 (6 to 15)8 (2 to 10)
SecondaryAim 2 (Phase 2): Feasibility of Pain Unpleasantness Outcome Data Collection

One of the secondary outcomes in Aim 2 (Phase 2) was to evaluate the feasibility of collecting data of clinical outcomes that would serve as the basis for efficacy evaluation of the interventions in future clinical trials. We evaluated the ability to collect 3 subjective clinical outcomes: pain intensity, pain unpleasantness, and anxiety scores immediately before a technology session preoperatively and immediately before, immediately after, 15-minutes after, and 30-minutes after a technology session after surgery in both treatment arms. Preoperatively, scores were collected only at one time point during the 5 preoperative days. In this measure, we evaluated the number of participants reporting at least one pain unpleasantness score for each time point during study participation. Because this study was a study designed to assess feasibility, we did not evaluate/analyze the scores themselves but rather our ability to collect data from participants

Time frame:
Up to 2 weeks before surgery and up to 2 weeks after surgery
Reported as:
Count of participants · Participants
Aim 2 (Phase 2): Feasibility of Pain Unpleasantness Outcome Data Collection
ParticipantsTechnology Based Intervention 1 (Phase 2)Technology Based Intervention 2 (Phase 2)
Preoperative, immediately before session2621
Postoperative, immediately before session3527
Postoperative, immediately after session3524
Postoperative, 15 minutes after session3524
Postoperative, 30 minutes after session3524
SecondaryAim 2 (Phase 2): Feasibility of Pain Unpleasantness Outcome Data Collection, Continued

One of the secondary outcomes in Aim 2 (Phase 2) of the study was to evaluate the feasibility of collecting data of clinical outcomes that would serve as the basis for efficacy evaluation of the interventions in future clinical trials. We evaluated the ability to collect 3 subjective clinical outcomes: pain intensity, pain unpleasantness, and anxiety scores immediately before a technology session preoperatively and immediately before, immediately after, 15-minutes after, and 30-minutes after a technology session after surgery in both treatment arms. In this measure, we evaluated the median number of pain unpleasantness scores reported by participants for each time point after surgery during their study participation as a median, IQR. Because this study was a study designed to assess feasibility, we did not evaluate/analyze the scores themselves but rather our ability to collect the data.

Time frame:
Up to 2 weeks after surgery
Reported as:
Median · # of pain unpleasantness scores reported
Aim 2 (Phase 2): Feasibility of Pain Unpleasantness Outcome Data Collection, Continued
# of pain unpleasantness scores reportedTechnology Based Intervention 1 (Phase 2)Technology Based Intervention 2 (Phase 2)
Postoperative, immediately before session12 (6 to 16)12 (4 to 16)
Postoperative, immediately after session10 (6 to 15)8 (2 to 10)
Postoperative, 15 minutes after session10 (6 to 15)8 (2 to 10)
Postoperative, 30 minutes after session10 (6 to 15)8 (2 to 10)
SecondaryAim 2 (Phase 2): Feasibility of Pain Intensity Outcome Data Collection

One of the secondary outcomes in Aim 2 (Phase 2) was to evaluate the feasibility of collecting data of clinical outcomes that would serve as the basis for efficacy evaluation of the interventions in future clinical trials. We evaluated the ability to collect 3 subjective clinical outcomes: pain intensity, pain unpleasantness, and anxiety scores immediately before a technology session preoperatively and immediately before, immediately after, 15-minutes after, and 30-minutes after a technology session after surgery in both treatment arms. Preoperatively, scores were collected only at one time point during the 5 preoperative days. In this measure, we evaluated the number of participants reporting at least one pain intensity score for each time point during study participation. Because this study was a study designed to assess feasibility, we did not evaluate/analyze the scores themselves but rather our ability to collect data from participants.

Time frame:
Up to 2 weeks before surgery and up to 2 weeks after surgery
Reported as:
Count of participants · Participants
Aim 2 (Phase 2): Feasibility of Pain Intensity Outcome Data Collection
ParticipantsTechnology Based Intervention 1 (Phase 2)Technology Based Intervention 2 (Phase 2)
Preoperative, immediately before session2621
Postoperative, immediately before session3527
Postoperative, immediately after session3524
Postoperative, 15 minutes after session3524
Postoperative, 30 minutes after session3524
SecondaryAim 2 (Phase 2): Feasibility of Pain Intensity Outcome Data Collection, Continued

One of the secondary outcomes in Aim 2 (Phase 2) of the study was to evaluate the feasibility of collecting data of clinical outcomes that would serve as the basis for efficacy evaluation of the interventions in future clinical trials. We evaluated the ability to collect 3 subjective clinical outcomes: pain intensity, pain unpleasantness, and anxiety scores immediately before a technology session preoperatively and immediately before, immediately after, 15-minutes after, and 30-minutes after a technology session after surgery in both treatment arms. In this measure, we evaluated the median number of pain intensity scores reported by participants for each time point after surgery during their study participation as a median, IQR. Because this study was a study designed to assess feasibility, we did not evaluate/analyze the scores themselves but rather our ability to collect the data.

Time frame:
Up to 2 weeks after surgery
Reported as:
Median · # of pain intensity scores reported
Aim 2 (Phase 2): Feasibility of Pain Intensity Outcome Data Collection, Continued
# of pain intensity scores reportedTechnology Based Intervention 1 (Phase 2)Technology Based Intervention 2 (Phase 2)
Postoperative, immediately before session12 (6 to 16)12 (4 to 16)
Postoperative, immediately after session10 (6 to 15)8 (2 to 10)
Postoperative, 15 minutes after session10 (6 to 15)8 (2 to 10)
Postoperative, 30 minutes after session10 (6 to 15)8 (2 to 10)
SecondaryAim 2 (Phase 2): Feasibility of Medication Use Data Collection

One of the secondary outcomes in Aim 2 (Phase 2) of the study was to evaluate the feasibility of collecting data of clinical outcomes that would serve as the basis for efficacy evaluation of the interventions in future clinical trials. We evaluated the ability to collect opioid use postoperatively. In this measure, we evaluated the number of patients in which opioid use data was successfully collected after surgery.

Time frame:
Post-intervention up to 7 days
Reported as:
Count of participants · Participants
Aim 2 (Phase 2): Feasibility of Medication Use Data Collection
ParticipantsTechnology Based Intervention 1 (Phase 2)Technology Based Intervention 2 (Phase 2)
Aim 2 (Phase 2): Feasibility of Medication Use Data Collection3530

Adverse events

Collected over 1 month. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Technology Based Intervention 1 (Phase 1)0/23 (0%)0/23 (0%)0/23 (0%)
Technology Based Intervention 1 (Phase 2)0/39 (0%)0/39 (0%)0/39 (0%)
Technology Based Intervention 2 (Phase 2)0/31 (0%)0/31 (0%)0/31 (0%)

Baseline characteristics

Age, Categorical
Age, Categorical(Participants)Technology Based Intervention 1 (Aim 1/Phase 1)Technology Based Intervention 1 (Aim 2/Phase 2)Technology Based Intervention 2 (Aim 2/Phase 2)Total
<=18 years23393193
Between 18 and 65 years0000
>=65 years0000
Age, Continuous
Age, Continuous(years)Technology Based Intervention 1 (Aim 1/Phase 1)Technology Based Intervention 1 (Aim 2/Phase 2)Technology Based Intervention 2 (Aim 2/Phase 2)Total
Mean15.5 ± 1.816.2 ± 1.815.4 ± 1.915.9 ± 1.9
Sex: Female, Male
Sex: Female, Male(Participants)Technology Based Intervention 1 (Aim 1/Phase 1)Technology Based Intervention 1 (Aim 2/Phase 2)Technology Based Intervention 2 (Aim 2/Phase 2)Total
Female16182357
Male721836
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Technology Based Intervention 1 (Aim 1/Phase 1)Technology Based Intervention 1 (Aim 2/Phase 2)Technology Based Intervention 2 (Aim 2/Phase 2)Total
American Indian or Alaska Native0101
Asian1102
Native Hawaiian or Other Pacific Islander0000
Black or African American34310
White19302675
More than one race0101
Unknown or Not Reported0224
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Technology Based Intervention 1 (Aim 1/Phase 1)Technology Based Intervention 1 (Aim 2/Phase 2)Technology Based Intervention 2 (Aim 2/Phase 2)Total
Hispanic or Latino1225
Not Hispanic or Latino22362987
Unknown or Not Reported0101
Region of Enrollment
Region of Enrollment(participants)Technology Based Intervention 1 (Aim 1/Phase 1)Technology Based Intervention 1 (Aim 2/Phase 2)Technology Based Intervention 2 (Aim 2/Phase 2)Total
United States23393193
08

Study locations

1 site
  • Nemours Children's Hospital
    Wilmington, Delaware 19803, United States
09

References and documents

Publications

  • Lin AM, Rachwal B, Asti L, Orgil Z, Santiago I, Ding L, Kashikar-Zuck S, King CD, Williams SE, Black WR, Minneci PC, Olbrecht VA. Feasibility and Acceptability of Perioperative Application of Biofeedback-Based Virtual Reality vs Control for Pain and Anxiety in Children and Adolescents Undergoing Surgery: Pilot Randomized Controlled Trial. J Med Internet Res. 2026 Sep 16;28:e94604. doi: 10.2196/94604. PubMed 42748484 ↗
  • Orgil Z, Karthic A, Bell NF, Heisterberg LM, Williams SE, Ding L, Kashikar-Zuck S, King CD, Olbrecht VA. Use of Biofeedback-Based Virtual Reality in Pediatric Perioperative and Postoperative Settings: Observational Study. JMIR Perioper Med. 2024 Sep 16;7:e48959. doi: 10.2196/48959. PubMed 38742940 ↗
  • Orgil Z, Johnson L, Karthic A, Williams SE, Ding L, Kashikar-Zuck S, King CD, Olbrecht VA. Feasibility and acceptability of perioperative application of biofeedback-based virtual reality versus active control for pain and anxiety in children and adolescents undergoing surgery: protocol for a pilot randomised controlled trial. BMJ Open. 2023 Jan 25;13(1):e071274. doi: 10.1136/bmjopen-2022-071274. PubMed 36697053 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No — IPD will not be shared with the public, but aggregate data will be publicly available upon request.

10

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Mar 2022 to primary completion in Aug 2025, 40 months.

Results were first posted in Oct 2026, 1 year 2 months after primary completion.

Of 3,749 non-industry interventional studies with no phase under Pain, half reached primary completion within 10 months of starting (the median), counting those still running; a quarter within 4 and three quarters within 23. This study's 40 months is above that.

Counting every sponsor, half of 3,848 studies reached it within 10 months; a quarter within 4 and three quarters within 23.

How these figures are worked out, and which studies are left out of them.

Registered
May 17, 2021
First posted
Jun 29, 2021
StartActual
Mar 10, 2022
Primary completionActual
Aug 6, 2025
CompletionActual
Aug 22, 2025
Results first posted
Oct 20, 2026
Last update
Oct 20, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Results
Results posted
posted Oct 20, 2026
Primary outcomes
2 edited, 1 removed
What changed in the outcomes
  • EditedAim 1 (Phase 1): Treatment protocol refinementProtocol RefinementTime frame: Duration of study up to 30 days → From two weeks before surgery up to 30 days after surgery
  • EditedAim 2 (Phase 2): Feasibility of technology interventionTechnology Intervention in perioperative patientsPerioperative PatientsTime frame: Pre-intervention → From two weeks before surgery until 30 days after surgery
  • RemovedAim 1: Treatment protocol refinementTime frame: Duration of study up to 30 days
Oct 20, 2026
Publications
1 publication citing this study linked from PubMed, e.g. PubMed 42748484 ↗
Oct 20, 2026
Secondary outcomes
9 edited, 17 added, 4 removed, 5 more
What changed in the outcomes
  • EditedAim 1 (Phase 1): Preoperative training protocolTraining ProtocolTime frame: Up to two weeks pre-operatively → Up to two weeks before surgery
  • EditedAim 1 (Phase 1): Preoperative training protocolTraining Protocol, ContinuedTime frame: Up to two weeks pre-operatively → Up to two weeks before surgery
  • EditedAim 1 (Phase 1): Post-operative session protocolSession ProtocolTime frame: Up to two week post surgery → Up to two weeks after surgery
  • EditedAim 1 (Phase 1): Post-operative session protocolSession Protocol, ContinuedTime frame: Up to two weeks post surgery → Up to two weeks after surgery
  • EditedAim 2 (Phase 2): Rate of study enrollmentStudy Enrollment/randomizationRandomizationTime frame: Pre-intervention → Pre-intervention up to 2 weeks before surgery
  • EditedAim 2 (Phase 2): Rate of study retentionStudy RetentionTime frame: Duration of study up to 30 days → From two weeks before surgery up to 30 days after surgery
  • EditedAim 2 (Phase 2): Rate of treatment adherenceTreatment Adherence (Preoperative)Time frame: Duration of study up to 30 days → Up to 2 weeks before surgery
  • EditedAim 2 (Phase 2): Treatment-specific satisfactionSatisfactionTime frame: Post intervention up to two weeks → Duration of study participation up to 30 days
  • EditedAim 2 (Phase 2): EffectFeasibility of technology on medication useMedication Use Data CollectionTime frame: Duration of hospital stay (2-7 days) → Post-intervention up to 7 days
  • AddedAim 1 (Phase 1): Preoperative Training Protocol, ContinuedTime frame: Up to two weeks before surgery
  • AddedAim 1 (Phase 1): Preoperative Training Protocol, ContinuedTime frame: Up to two weeks before surgery
  • AddedAim 1 (Phase 1): Post-operative Session Protocol, ContinuedTime frame: Up to two weeks after surgery
  • AddedAim 1 (Phase 1): Postoperative Session Protocol, ContinuedTime frame: Up to two weeks after surgery
  • AddedAim 2 (Phase 2): Treatment Adherence, Continued (Preoperative)Time frame: Up to two weeks before surgery
  • AddedAim 2 (Phase 2): Treatment Adherence, Continued (Preoperative)Time frame: Up to two weeks before surgery
  • AddedAim 2 (Phase 2): Rate of Treatment Adherence (Post-operative)Time frame: Up to 30 days after surgery
  • AddedAim 2 (Phase 2): Treatment Adherence, Continued (Post-operative)Time frame: Up to 30 days after surgery
  • AddedAim 2 (Phase 2): Treatment Adherence, Continued (Post-operative)Time frame: Up to 30 days after surgery
  • AddedAim 2 (Phase 2): Treatment Adherence, Continued (Post-operative)Time frame: Up to 30 days
  • AddedAim 2 (Phase 2): Treatment Adherence, Continued (Post-operative)Time frame: Up to 30 days after surgery
  • AddedAim 2 (Phase 2): Feasibility of Anxiety Outcome Data CollectionTime frame: Up to 2 weeks before surgery and up to 2 weeks after surgery
  • AddedAim 2 (Phase 2): Feasibility of Anxiety Outcome Data Collection, ContinuedTime frame: Up to 2 weeks after surgery
  • AddedAim 2 (Phase 2): Feasibility of Pain Unpleasantness Outcome Data CollectionTime frame: Up to 2 weeks before surgery and up to 2 weeks after surgery
  • AddedAim 2 (Phase 2): Feasibility of Pain Unpleasantness Outcome Data Collection, ContinuedTime frame: Up to 2 weeks after surgery
  • AddedAim 2 (Phase 2): Feasibility of Pain Intensity Outcome Data CollectionTime frame: Up to 2 weeks before surgery and up to 2 weeks after surgery
  • AddedAim 2 (Phase 2): Feasibility of Pain Intensity Outcome Data Collection, ContinuedTime frame: Up to 2 weeks after surgery
  • RemovedAim 2: Treatment-specific satisfactionTime frame: Post intervention up to two weeks
  • RemovedAim 2: Effect of technology on anxietyTime frame: 30 minutes after using technology
  • RemovedAim 2: Effect of technology on anxietyTime frame: Before using technology
  • RemovedAim 2: Effect of technology on anxietyTime frame: Immediately after using technology
  • …and 5 more, on the record history on ClinicalTrials.gov ↗
Oct 20, 2026
Show all 1 update
  1. Oct 20, 2026
    Results posted
    Publications 1 publication citing this study linked from PubMed, e.g. PubMed 42748484 ↗
    Primary outcomes 2 edited, 1 removed
    What changed in the outcomes
    • EditedAim 1 (Phase 1): Treatment protocol refinementProtocol RefinementTime frame: Duration of study up to 30 days → From two weeks before surgery up to 30 days after surgery
    • EditedAim 2 (Phase 2): Feasibility of technology interventionTechnology Intervention in perioperative patientsPerioperative PatientsTime frame: Pre-intervention → From two weeks before surgery until 30 days after surgery
    • RemovedAim 1: Treatment protocol refinementTime frame: Duration of study up to 30 days
    Secondary outcomes 9 edited, 17 added, 4 removed, 5 more
    What changed in the outcomes
    • EditedAim 1 (Phase 1): Preoperative training protocolTraining ProtocolTime frame: Up to two weeks pre-operatively → Up to two weeks before surgery
    • EditedAim 1 (Phase 1): Preoperative training protocolTraining Protocol, ContinuedTime frame: Up to two weeks pre-operatively → Up to two weeks before surgery
    • EditedAim 1 (Phase 1): Post-operative session protocolSession ProtocolTime frame: Up to two week post surgery → Up to two weeks after surgery
    • EditedAim 1 (Phase 1): Post-operative session protocolSession Protocol, ContinuedTime frame: Up to two weeks post surgery → Up to two weeks after surgery
    • EditedAim 2 (Phase 2): Rate of study enrollmentStudy Enrollment/randomizationRandomizationTime frame: Pre-intervention → Pre-intervention up to 2 weeks before surgery
    • EditedAim 2 (Phase 2): Rate of study retentionStudy RetentionTime frame: Duration of study up to 30 days → From two weeks before surgery up to 30 days after surgery
    • EditedAim 2 (Phase 2): Rate of treatment adherenceTreatment Adherence (Preoperative)Time frame: Duration of study up to 30 days → Up to 2 weeks before surgery
    • EditedAim 2 (Phase 2): Treatment-specific satisfactionSatisfactionTime frame: Post intervention up to two weeks → Duration of study participation up to 30 days
    • EditedAim 2 (Phase 2): EffectFeasibility of technology on medication useMedication Use Data CollectionTime frame: Duration of hospital stay (2-7 days) → Post-intervention up to 7 days
    • AddedAim 1 (Phase 1): Preoperative Training Protocol, ContinuedTime frame: Up to two weeks before surgery
    • AddedAim 1 (Phase 1): Preoperative Training Protocol, ContinuedTime frame: Up to two weeks before surgery
    • AddedAim 1 (Phase 1): Post-operative Session Protocol, ContinuedTime frame: Up to two weeks after surgery
    • AddedAim 1 (Phase 1): Postoperative Session Protocol, ContinuedTime frame: Up to two weeks after surgery
    • AddedAim 2 (Phase 2): Treatment Adherence, Continued (Preoperative)Time frame: Up to two weeks before surgery
    • AddedAim 2 (Phase 2): Treatment Adherence, Continued (Preoperative)Time frame: Up to two weeks before surgery
    • AddedAim 2 (Phase 2): Rate of Treatment Adherence (Post-operative)Time frame: Up to 30 days after surgery
    • AddedAim 2 (Phase 2): Treatment Adherence, Continued (Post-operative)Time frame: Up to 30 days after surgery
    • AddedAim 2 (Phase 2): Treatment Adherence, Continued (Post-operative)Time frame: Up to 30 days after surgery
    • AddedAim 2 (Phase 2): Treatment Adherence, Continued (Post-operative)Time frame: Up to 30 days
    • AddedAim 2 (Phase 2): Treatment Adherence, Continued (Post-operative)Time frame: Up to 30 days after surgery
    • AddedAim 2 (Phase 2): Feasibility of Anxiety Outcome Data CollectionTime frame: Up to 2 weeks before surgery and up to 2 weeks after surgery
    • AddedAim 2 (Phase 2): Feasibility of Anxiety Outcome Data Collection, ContinuedTime frame: Up to 2 weeks after surgery
    • AddedAim 2 (Phase 2): Feasibility of Pain Unpleasantness Outcome Data CollectionTime frame: Up to 2 weeks before surgery and up to 2 weeks after surgery
    • AddedAim 2 (Phase 2): Feasibility of Pain Unpleasantness Outcome Data Collection, ContinuedTime frame: Up to 2 weeks after surgery
    • AddedAim 2 (Phase 2): Feasibility of Pain Intensity Outcome Data CollectionTime frame: Up to 2 weeks before surgery and up to 2 weeks after surgery
    • AddedAim 2 (Phase 2): Feasibility of Pain Intensity Outcome Data Collection, ContinuedTime frame: Up to 2 weeks after surgery
    • RemovedAim 2: Treatment-specific satisfactionTime frame: Post intervention up to two weeks
    • RemovedAim 2: Effect of technology on anxietyTime frame: 30 minutes after using technology
    • RemovedAim 2: Effect of technology on anxietyTime frame: Before using technology
    • RemovedAim 2: Effect of technology on anxietyTime frame: Immediately after using technology
    • …and 5 more, on the record history on ClinicalTrials.gov ↗
    + 3 other changes: verification date, index terms and registry notes

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

11

Registry details

Key details

Study ID
NCT04943874
Lead sponsor
Vanessa Olbrecht
Responsible party
Vanessa Olbrecht (Chair, Department of Anesthesiology & Perioperative Medicine, Nemours Children's Clinic) — Sponsor-investigator
First posted
Jun 29, 2021
Start date
Mar 10, 2022
Primary completion
Aug 6, 2025
Completion
Aug 22, 2025
Results posted
Oct 20, 2026
Last update
Oct 20, 2026

Study contacts

Vanessa Olbrecht, MD
principal investigator · Nemours Children's Hospital

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion